TALazoparib and Avelumab as Maintenance Therapy in Platinum-Sensitive Metastatic or Locally Advanced URothelial Carcinoma: A Single-arm Phase 2 Trial
Latest Information Update: 13 Aug 2024
At a glance
- Drugs Avelumab (Primary) ; Talazoparib (Primary)
- Indications Bladder cancer; Carcinoma; Pelvic cancer; Renal cancer; Ureteral neoplasms; Urethral cancer; Urogenital cancer
- Focus Therapeutic Use
- Acronyms TALASUR
- 08 Aug 2024 Planned End Date changed from 1 Dec 2023 to 1 Dec 2025.
- 24 Nov 2022 Trial design, published in the BMC Cancer
- 09 Aug 2022 Planned End Date changed from 1 Dec 2022 to 1 Dec 2023.